Sanofi (NASDAQ:SNY) Lowered to Buy Rating by StockNews.com

Sanofi (NASDAQ:SNY) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

SNY has been the subject of several other research reports. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Down 3.0 %

SNY opened at $51.26 on Thursday. The stock’s fifty day simple moving average is $55.78 and its 200 day simple moving average is $52.15. Sanofi has a 1-year low of $45.00 and a 1-year high of $58.97. The stock has a market cap of $130.09 billion, a PE ratio of 26.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.55 EPS. As a group, research analysts expect that Sanofi will post 4.27 earnings per share for the current year.

Institutional Trading of Sanofi

A number of hedge funds have recently made changes to their positions in SNY. Atlanta Consulting Group Advisors LLC acquired a new position in shares of Sanofi during the third quarter worth $1,111,000. Natixis Advisors LLC raised its position in Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. Simplify Asset Management Inc. acquired a new position in Sanofi during the 3rd quarter worth about $11,765,000. Arjuna Capital bought a new stake in shares of Sanofi in the 3rd quarter valued at about $2,245,000. Finally, Angeles Investment Advisors LLC increased its stake in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after buying an additional 210 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.